Genmab reports trial results for ovarian cancer drug candidate
COPENHAGEN - Genmab A/S revealed results from the final stage of its Phase 1/2 trial, RAINFOL-01, assessing rinatabart sesutecan (Rina-S) for platinum-resistant ovarian cancer patients. The study involved 109 patients who had undergone one to three previous treatments. The drug achieved a confirmed objective response rate of 45.9%, with five patients experiencing complete remission.
The median time to response was 12.1 months, and 51% of responders maintained their response for a year. Median progression-free survival reached 9.5 months. Over half of the participants (53%) had received three or four prior treatments, including platinum-resistant ovarian cancer, endometrial cancer, and platinum-sensitive ovarian cancer.
Symptoms such as fatigue, nausea, anemia, and neutropenia were commonly reported. Notably, no instances of significant adverse effects like ocular toxicity, peripheral neuropathy, interstitial lung disease, or stomatitis were observed. Rina-S, an antibody-drug conjugate targeting folate receptor alpha, is part of Genmab's clinical development program, which includes trials for various gynecologic cancers. However, the safety and efficacy of Rina-S have yet to be fully established.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.